Literature DB >> 9013407

Alpha 1-antichymotrypsin gene polymorphism and risk for Alzheimer's disease.

T Muramatsu1, S Matsushita, H Arai, H Sasaki, S Higuchi.   

Abstract

alpha 1-Antichymotrypsin (ACT), a component of the senile plaque of the Alzheimer's disease (AD) brain, has a possible role as a molecular chaperone in developing AD pathology. This study was a search for the possible association of the two structural polymorphisms of ACT, Ala15-->Thr and Met389-->Val in the Japanese population. In 101 AD patients, genotype and allele frequencies of the two polymorphisms did not differ from those of 104 age-matched healthy controls. However, in those subjects in which the apolipoprotein epsilon 4 allele was absent, the frequency of the Ala15 homozygote was significantly higher in the AD patients than in controls. This suggests that the Ala15 homozygote state may be a susceptibility marker for AD, interacting with apolipoprotein E genotype.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9013407     DOI: 10.1007/BF01271205

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  19 in total

1.  Unity in function in the absence of consensus in sequence: role of leader peptides in export.

Authors:  L L Randall; S J Hardy
Journal:  Science       Date:  1989-03-03       Impact factor: 47.728

2.  Detection of a new mutant alpha-1-antichymotrypsin in patients with occlusive-cerebrovascular disease.

Authors:  M Tsuda; Y Sei; M Yamamura; M Yamamoto; Y Shinohara
Journal:  FEBS Lett       Date:  1992-06-08       Impact factor: 4.124

3.  Apolipoprotein E genotyping by one-stage PCR.

Authors:  P R Wenham; W H Price; G Blandell
Journal:  Lancet       Date:  1991-05-11       Impact factor: 79.321

4.  Distribution pattern and functional state of alpha 1-antichymotrypsin in plaques and vascular amyloid in Alzheimer's disease. A immunohistochemical study with monoclonal antibodies against native and inactivated alpha 1-antichymotrypsin.

Authors:  J M Rozemuller; J J Abbink; A M Kamp; F C Stam; C E Hack; P Eikelenboom
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

5.  The apolipoprotein epsilon 4 allele in patients with Alzheimer's disease.

Authors:  R Mayeux; Y Stern; R Ottman; T K Tatemichi; M X Tang; G Maestre; C Ngai; B Tycko; H Ginsberg
Journal:  Ann Neurol       Date:  1993-11       Impact factor: 10.422

6.  Alpha-1-antichymotrypsin bi-allele polymorphism, apolipoprotein-E tri-allele polymorphism and genetic risk of Alzheimer's syndrome.

Authors:  J Thome; A Baumer; J Kornhuber; M Rösler; P Riederer
Journal:  J Neural Transm Park Dis Dement Sect       Date:  1995

7.  A special type of senile plaque, possibly an initial stage.

Authors:  A Probst; H Brunnschweiler; C Lautenschlager; J Ulrich
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

8.  Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro.

Authors:  T Wisniewski; E M Castaño; A Golabek; T Vogel; B Frangione
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

9.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

10.  Polymorphism in AACT gene may lower age of onset of Alzheimer's disease.

Authors:  C Talbot; H Houlden; N Craddock; R Crook; M Hutton; C Lendon; G Prihar; J C Morris; J Hardy; A Goate
Journal:  Neuroreport       Date:  1996-01-31       Impact factor: 1.837

View more
  1 in total

1.  Apolipoprotein E epsilon 4 allele distribution in Wernicke-Korsakoff syndrome with or without global intellectual deficits.

Authors:  T Muramatsu; M Kato; T Matsui; H Yoshimasu; A Yoshino; S Matsushita; S Higuchi; H Kashima
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.